M. Alexander Otto's profile photo

M. Alexander Otto

Seattle

Medical Journalist at Medscape

Physician Assistant, journalist. MIT fellow, Medscape/ WebMD, McClatchy, Bloomberg, Washington Post.

Featured in: Favicon mdedge.com Favicon medscape.com (+3) Favicon thenewstribune.com Favicon the-hospitalist.org Favicon realclearhealth.com Favicon familypracticenews.com Favicon pediatricnews.com Favicon clinicalpsychiatrynews.com Favicon clinicalendocrinologynews.com Favicon obgynnews.com

Articles

  • Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

    1 week ago | medscape.com | M. Alexander Otto

    Treatment with pembrolizumab and the antibody-drug conjugate (ADC) sacituzumab govitecan improved progression-free survival (PFS) in patients with PD-L1-positive locally advanced or metastatic triple-negative breast cancer (TNBC) compared with treatment with pembrolizumab and chemotherapy, the results of ASCENT-04/KEYNOTE-D19 showed.

  • FDA Slams Pfizer for Talzenna Biomarker-Free Push

    1 week ago | medscape.com | M. Alexander Otto

    Pfizer was taken to task at a recent meeting of the US Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee (ODAC) for attempting to expand the use of its prostate cancer drug talazoparib (Talzenna) to men lacking a key biomarker without providing sufficient evidence of benefit.

  • FDA Questions Single-Arm Studies for Cancer Approvals

    2 weeks ago | medscape.com | M. Alexander Otto

    The US Food and Drug Administration’s (FDA’s) approval decision about a new treatment for non–muscle invasive bladder cancer (NMIBC) hinges on whether a single-armed trial can be trusted to adequately demonstrate risks and benefits.

  • Daratumumab Wins, Glofitamab Loses

    2 weeks ago | medscape.com | M. Alexander Otto

    Daratumumab and hyaluronidase (Darzalex Faspro, Johnson & Johnson) came a step closer to being approved for high-risk smoldering multiple myeloma (SMM) on Tuesday after the Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA) voted that the benefits outweigh the risks.

  • Retifanlimab Wins Upfront Indication for Anal Cancer

    3 weeks ago | medscape.com | M. Alexander Otto

    The US Food and Drug Administration has approved two new indications for the PD-1-blocking antibody, retifanlimab-dlwr (Zynyz, Incyte), both for locally recurrent or metastatic squamous cell anal carcinoma. The first indication is for upfront treatment of inoperable disease in combination with carboplatin and paclitaxel; the second is as monotherapy following progression on or intolerance to platinum-based chemotherapy.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
161
Tweets
271
DMs Open
Yes
M. Alexander Otto
M. Alexander Otto @MAlexanderOtto
15 Jun 23

important study for oncologists https://t.co/PdlN59TZlo

M. Alexander Otto
M. Alexander Otto @MAlexanderOtto
9 Dec 22

[tweet to keep acct active]

M. Alexander Otto
M. Alexander Otto @MAlexanderOtto
17 Apr 20

Fresh of the press. Indeed, it is a nasty little bug, but things are looking up on Long Island, anyways. Can you imagine 70 people all intubated at once? Like a sci-fi nightmare... @MDEdgeTweets @AmerMedicalAssn @Medscape @ivanoransky @hmkyale https://t.co/qKf5eZAwa8